Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBITDA: 2020-2025

Historic EBITDA for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$15.8 million.

  • Foghorn Therapeutics' EBITDA rose 14.35% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year increase of 18.56%. This contributed to the annual value of -$85.7 million for FY2024, which is 10.08% up from last year.
  • Per Foghorn Therapeutics' latest filing, its EBITDA stood at -$15.8 million for Q3 2025, which was up 12.30% from -$18.0 million recorded in Q2 2025.
  • Foghorn Therapeutics' EBITDA's 5-year high stood at -$13.5 million during Q3 2023, with a 5-year trough of -$29.4 million in Q1 2023.
  • For the 3-year period, Foghorn Therapeutics' EBITDA averaged around -$21.2 million, with its median value being -$19.7 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 64.66% in 2021, then skyrocketed by 50.74% in 2023.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' EBITDA stood at -$29.1 million in 2021, then increased by 3.88% to -$28.0 million in 2022, then grew by 17.74% to -$23.0 million in 2023, then increased by 14.37% to -$19.7 million in 2024, then increased by 14.35% to -$15.8 million in 2025.
  • Its EBITDA was -$15.8 million in Q3 2025, compared to -$18.0 million in Q2 2025 and -$19.0 million in Q1 2025.